Odds Are Stacked Against Matrixx In Bid To Rescind Zicam Warning Letter

Matrixx Initiatives faces long odds against convincing FDA to withdraw a warning letter concerning the firm's Zicam intranasal products, food and drug lawyers say after the firm's request was rejected a second time